Alerta

CANCER THERAPY WITH LIVE ATTENUATED BACTERIA

Resumen de: US2025064866A1

The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.

BREAST MILK-DERIVED LIMOSILACTOBACILLUS FERMENTUM MSJK0025 CAPABLE OF IMPROVING INTESTINAL FLORA CONDITION AND USE THEREOF

Resumen de: WO2025039454A1

A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric/intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.

MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS

Resumen de: US2025066429A1

The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

A MAPS VACCINE TARGETING SALMONELLA ENTERICA SEROVARS

Resumen de: US2025064910A1

Technologies for the prevention and/or treatment of Salmonella infections.

STABLE SALMONELLA VACCINE FORMULATIONS

Resumen de: WO2025042889A1

The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.

DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF

Resumen de: EP4512482A2

The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being:- devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and- substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group.It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.

Shenjing pig combined lactobacillus and application thereof

Resumen de: CN119506141A

The invention discloses a strain of Shenjing pig combined lactobacillus and application thereof. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.31452. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age and is sensitive to various common antibiotics, and fermented supernate of the strain shows relatively strong inhibition capability on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi B and gardnerella vaginalis; the compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of amino acid and bioactive substances such as peptides, arachidonic acids, steroids and polyketones can be greatly increased, the strain has an obvious inhibition effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in biological agents, but also opens up a new way for combined application of lactic acid bacteria and ganoderma spores.

SLAMP primer group and kit for detecting salmonella

Resumen de: CN119506449A

The invention provides an SLAMP primer group and a kit for detecting salmonella, and relates to the technical field of biological detection. The SLAMP primer group is a primer group aiming at the amplification of a conserved region fragment of salmonella, and is a primer pair SAL-SF/SAL-SR; wherein the nucleotide sequence of the SAL-SF is as shown in SEQ ID NO. 1, and the nucleotide sequence of the SAL-SR is as shown in SEQ ID NO. 2. According to the method or the kit provided by the invention, the salmonella can be rapidly and accurately detected without expensive instruments or complicated operation, so that the method or the kit is suitable for on-site rapid detection of ports, communities and the like with low professional degree. According to the visual kit provided by the invention, great convenience is provided for field detection, and rapid and accurate non-diagnostic purpose detection of salmonella can be realized.

Eutectic of L-carnitine and plant essential oil active ingredients as well as preparation method and application of eutectic

Resumen de: CN119504470A

The invention relates to the technical field of compound eutectic crystals, and discloses an L-carnitine and plant essential oil active component eutectic crystal and a preparation method and application thereof. The eutectic crystal is prepared from the following raw materials: L-carnitine and plant essential oil active ingredients, the molar ratio of the L-carnitine to the active ingredients of the plant essential oil is 1: 1; the plant essential oil active component is selected from at least one of thymol and carvacrol. The eutectic crystal provided by the invention is formed by at least one of thymol and carvacrol and L-carnitine, is low in hygroscopicity and volatility and good in stability, and overcomes the defects that single L-carnitine is strong in hygroscopicity and inconvenient to process and store, and single thymol or carvacrol is strong in volatility and poor in stability; compared with single thymol or carvacrol, the eutectic crystal shows lower minimum inhibitory concentration on escherichia coli, candida albicans, salmonella enteritidis, aspergillus niger and the like, and has a good antibacterial effect.

Saliva combined lactobacillus 8-2 strain and application thereof

Resumen de: CN119506144A

The invention provides a combined lactobacillus salivarius strain 8-2 and an application of the combined lactobacillus salivarius strain 8-2. The combined lactobacillus salivarius strain 8-2 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the combined lactobacillus salivarius strain 8-2 is CGMCC NO.30612. The invention further provides a preparation method of the combined lactobacillus salivarius strain 8-2. The lactobacillus salivarius disclosed by the invention has the advantages of good acid resistance, no hemolysis and relatively strong antibacterial ability, can relieve injury caused by salmonella infection, can effectively promote the absorption function of intestinal mucosa, improves the production performance of laying hens, and improves the production efficiency of the laying hens. The strain has the potential of being developed into a laying hen high-quality probiotic preparation with an anti-replacement function and a function of promoting intestinal mucosal injury repair, and can be applied to preparation of laying hen antibiotic substitutes, including application of strain fermentation supernatant in preparation of laying hen antibiotic substitutes.

Recombinant salmonella choleraesuis nuclease regulation vector as well as construction method and application thereof

Resumen de: CN119506315A

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

Nucleic acid detection kit for typhoid fever, paratyphoid fever, cholera, shiga and dysentery and application

Resumen de: CN119506446A

The invention discloses a nucleic acid detection kit for typhoid fever, paratyphoid fever, cholera, shigella and dysentery. The nucleic acid detection kit comprises a multiple fluorescent PCR detection system, and the multiple fluorescent PCR detection system comprises a typhoid fever salmonella primer probe, a paratyphoid fever salmonella primer probe, a vibrio cholera primer probe, a dysentery amoeba primer probe and a shigella primer probe; according to the kit, specific and conservative characteristic genes of different bacteria species are selected for primer probe design, so that the specificity, the accuracy and the sensitivity of detection are ensured.

Lactobacillus jensenii and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder

Resumen de: CN119506142A

The invention discloses a lactobacillus jensenii strain and application thereof in fermentation of wall-broken ganoderma lucidum spore powder. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.31484. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is sensitive to various common antibiotics, and has strong lactic acid production capacity; a fermentation supernatant of the bacillus subtilis shows relatively strong inhibition capability on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae, yersinia enterocolitica and gardnerella vaginalis, and has relatively strong adhesion capability, growth inhibition capability and apoptosis promotion effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of amino acid and bioactive substances such as peptides, arachidonic acids, steroids and polyketones can be greatly increased, the strain has an obvious inhibition effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in biological agents, but also opens up a new way for combined application of lactic acid bacteria and ganoderma spores.

一种重组鼠伤寒沙门氏菌的构建方法及其产品和应用

Resumen de: CN119491012A

本发明公开了一种重组鼠伤寒沙门氏菌的构建方法及其产品和应用，本发明中rSC0134(pS‑PlcC‑NetB)在免疫初期能够刺激机体产生充分的免疫应答，在免疫后期呈现出程序性的自我清除，具有一定安全性；rSC0134(pS‑PlcC‑NetB)免疫肉鸡后可产生强大的体液免疫，黏膜免疫和细胞免疫，保护肉鸡免受坏死性肠炎的感染；本发明构建了一种重组减毒鼠伤寒沙门氏菌疫苗载体平台，为开发针对鸡源传染病疫苗的递送平台提供了一种有前景的策略，具有较大的市场应用潜力和潜在的经济效益。

GENETICALLY MODIFIED BACTERIA FOR MULTI-MODAL SECRETION OF A NEOANTIGEN

Resumen de: WO2025037284A2

A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.

IMMUNOSTIMULATORY BACTERIA ENGINEERED TO COLONIZE TUMORS, TUMOR-RESIDENT IMMUNE CELLS, AND THE TUMOR MICROENVIRONMENT

Resumen de: AU2025200704A1

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion ofpagP or modification ofpagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin" and/orpagP'. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine and/or purine auxotrophs. The bacteria optionally are one or more of asct, purl'and msbB'. The immunostimulatory bacteria, such as Salmonella species, are modified to encode proteins that induce type I interferon (IFN) expression, or that are variants thereof that have increased activity to induce type I IFN expression, or that are variants thereof that result in constitutive expression of type I IFN. The bacteria can encode a modified Stimulator of Interferon Genes (STING) protein from a non-human species, that has lower NF-KB signaling activity, and, optionally, higher type I IFN pathway signaling activity, compared to human STING. The bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the

VEGFR-2 DNA VEGER-2 TARGETING DNA VACCINE FOR COMBINATION THERAPY

Resumen de: US2021077605A1

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.

yncJ基因在调控鼠伤寒沙门氏菌毒力中的应用

Resumen de: CN119464322A

本发明公开了yncJ基因在调控鼠伤寒沙门氏菌毒力中的应用，属于生物技术领域。本发明通过构建鼠伤寒沙门氏菌的yncJ基因缺失菌株对yncJ基因的功能进行研究，发现将yncJ基因缺失后，菌株在巨噬细胞内的增殖能力显著降低；通过感染小鼠实验发现，yncJ基因缺失菌株对小鼠的致死能力显著降低。而且，yncJ基因缺失菌株的常规生化特性和体外生长速度未见明显变化，因此，yncJ基因缺失菌株具有生产防治鼠伤寒沙门氏菌的减毒疫苗的应用前景。

一种装载肉桂醛的固液双相人工细胞制备及肠炎靶向治疗应用

Resumen de: CN119464306A

本发明提供一种装载肉桂醛的固液双相人工细胞(SL‑BACs)，其具有固相保护膜和液态多核，其利用微流体T型芯片，高效、稳定地制造获得。SL‑BACs可对鼠伤寒沙门氏菌诱发的结肠炎提供多方面治疗帮助，首先液态多核内的适配体在感染部位表现出精准靶向性；其次，SL‑BACs对肉桂醛的包封率较高，约为82.9％；再次，膜结构将SL‑BACs的肠道保留时间延长至15h；并且SL‑BACs表现出pH响应性，控制释放液态多核抗菌，其杀菌率为95.28％。SL‑BACs还能降低促炎细胞因子分泌，优化肠道微生物群组成，维持肠道稳态。总之，SL‑BACs为将人工细胞模块化成口服系统进行靶向治疗提供了必要条件。

Pediococcus acidilactici with acid resistance, cholate resistance and bacteriostatic activity and application thereof

Resumen de: CN119464158A

The invention belongs to the technical field of probiotics, and particularly relates to pediococcus acidilactici with acid resistance, bile salt resistance and antibacterial activity and application of the pediococcus acidilactici. The pediococcus acidilactici TR19 has the preservation number of CGMCC NO.31330 and is classified and named as pediococcus acidilactici according to microorganisms. The strain has good acid resistance and bile salt resistance, and can be used for preparing probiotics for preventing and treating bacteria. Meanwhile, the strain has a relatively strong bacteriostatic effect on escherichia coli, bacillus cereus, staphylococcus aureus and salmonella typhimurium, in addition, the strain has a relatively good degradation capability on nitrite and cholesterol, and the applicability is relatively strong.

Photonic crystal fluorescence sensor based on recombinase polymerase amplification and CRISPR/Cas12a system

Resumen de: CN119464523A

The invention relates to the technical field of salmonella detection, and provides a photonic crystal fluorescence sensor based on recombinase polymerase amplification and a CRISPR/Cas12a system, and the photonic crystal fluorescence sensor comprises a biosensing platform and a photonic crystal array; the reaction components of the biosensing platform comprise an RPA reagent, an upstream primer, a downstream primer, Cas12a protein, crRNA, an ssDNA probe and a buffer solution; the photonic crystal array is mainly constructed by a PDMS substrate, polystyrene microspheres, ethanol and a microwell plate analyzer; the detection sensitivity of the salmonella is obviously improved.

一种基于MIL(53)-Fe纳米酶活性的细菌检测方法及其应用

Resumen de: CN119470891A

本发明涉及一种基于MIL(53)‑Fe纳米酶活性的细菌检测方法。本发明的细菌检测方法通过将适配体与铁基金属有机骨架结合形成细菌探针，并利用MIL(53)‑Fe在过氧化氢存在的条件下将TMB催化生成TMB+的性能，同时将生成的TMB+酸化形成TMB2+，利用TMB2+对金纳米棒的蚀刻导致金纳米棒颜色发生变化，进而实现细菌的检测。该检测方法简单快捷，且对金黄色葡萄球菌的最低检测限为1.16CFU/mL，大肠杆菌的最低检测限为1.02CFU/mL，具有广阔的应用前景。除此以外，本发明的检测结果肉眼可见，可作为定性检测的依据。

Double-target simultaneous rapid detection method for escherichia coli and salmonella enteritidis

Resumen de: CN119464526A

The invention relates to the field of microbiological detection, in particular to a method for simultaneously and rapidly detecting at least two target objects, which comprises the following steps: S101, obtaining a first mixture; s102, obtaining a second mixture; s103, centrifuging the first mixture, collecting a first supernatant, centrifuging the second mixture, and collecting a second supernatant; s104, obtaining a third mixture; and S105, analyzing the existence and/or concentration of the first target object and/or the second target object in the sample to be detected according to the fluorescence intensity signal. The method has high detection sensitivity, good specificity, reproducibility, stability and anti-interference performance, and realizes enzyme-free, DNA-free, ultra-sensitive and wide-linear-range double-target detection.

Self-assembly preparation method and application of multi-enzyme active nano-zinc oxide for treating salmonella enteritis

Resumen de: CN119424475A

The invention discloses a self-assembly preparation method and application of multi-enzyme active nano-zinc oxide for treating salmonella enteritis, a trace amount of oleylamine is added as a protective agent, a self-assembly nano-enzyme is synthesized by a simple method, and the direct antibacterial effect of ZnO is improved; the minimal inhibitory concentration of ZnO synthesized by the same method in vitro is 250 mu g/mL, the minimal inhibitory concentration of ZnO doped with trace Cu and Mn is about 30 mu g/mL, and the bacteriostatic efficiency is improved by about 8 times; trace elements of copper (Cu) and manganese (Mn) are doped into a ZnO nano material, so that the ZnO nano material is endowed with various enzyme activities, peroxidase activity is exerted under the acidic condition of the stomach to generate bactericidal active oxygen, and superoxide dismutase and catalase activity for resisting oxidative stress are exerted when the ZnO nano material reaches neutral intestinal tracts, so that inflammation of the intestinal tracts is relieved; the traditional Chinese medicine composition can play a role in the acidic state of the stomach, can relieve inflammation of the intestinal tract in the intestinal tract, and can completely adapt to the environment of the gastrointestinal tract.

Microencapsulated bacteriophage embedding body prepared by adopting microjet technology, preparation method, embedding rate determination method and application

Nº publicación: CN119432772A 14/02/2025

Solicitante:

SHANDONG AGRICULTURAL UNIV
\u5C71\u4E1C\u519C\u4E1A\u5927\u5B66

Resumen de: CN119432772A

The invention provides a microencapsulated bacteriophage embedding body prepared by adopting a microjet technology, a preparation method, an embedding rate determination method and application, and relates to the technical field of biology, bacteriophage is embedded in calcium alginate to form the microencapsulated bacteriophage embedding body, the size of the microencapsulated bacteriophage embedding body is smaller than 200nm, and the microencapsulated bacteriophage embedding body is prepared by adopting a microjet technology. The microencapsulated phage embedding body is in a spherical shape; wherein the bacteriophage is CKT1, and the embedding rate of the bacteriophage in the microencapsulated bacteriophage embedding body is greater than 55%. According to the microencapsulated phage embedding body prepared by adopting a microjet technology, the obtained phage embedding body is relatively small in size and uniform in morphology, the phage CKT1 embedded by calcium alginate can keep normal activity, the stability of the phage CKT1 is enhanced, and the microencapsulated phage embedding body has a good application prospect in the aspect of treating and preventing chicken salmonella infection.